Inactive Instrument
ReNeuron Group Plc Stock London S.E.
Stocks
Biotechnology & Medical Research
OTC Markets Traded
| 24-02-06 | RENEURON ISSUES ADMINISTRATION WARNING | AQ |
| 23-11-27 | Edison issues update on ReNeuron Group (RENE): H124 results reaffirm focus on CustomEX™ | EQ |
| 23-11-16 | ReNeuron : Interim Statement 2023 | PU |
| 23-11-07 | ReNeuron : Presentation | PU |
| 23-07-24 | ReNeuron : 24 July 2023 – Notice of Annual General Meeting | PU |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 2025-03-23 |
| Director | Title | Age | Since |
|---|---|---|---|
Iain Ross
CHM | Chairman | 72 | 2021-06-30 |
| Director/Board Member | 63 | 2021-07-13 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 2.58M | |
| -6.60% | -8.56% | +49.38% | +63.51% | 65B | |
| -4.09% | -0.11% | +2.22% | +53.15% | 51.19B | |
| +0.03% | +5.56% | +9.10% | +69.05% | 51.2B | |
| -1.53% | +2.70% | +30.48% | +34.12% | 43.93B | |
| -1.34% | +4.12% | +16.64% | +115.13% | 41.96B | |
| -5.97% | -6.22% | +228.95% | +454.22% | 38.14B | |
| +6.53% | +8.02% | +16.40% | +53.41% | 33.24B | |
| -0.90% | -10.49% | +37.09% | -3.70% | 25.2B | |
| -2.76% | -9.54% | -16.58% | -9.19% | 22.03B | |
| Average | -1.66% | -1.67% | +41.52% | +92.19% | 41.32B | |
| Weighted average by Cap. | -2.30% | -1.21% | +42.14% | +95.51% |
Employees
-
